GLP-1 Maintenance Dosing: A Key to Effective Treatment

Verify that patients currently prescribed Wegovy or Zepbound have reached and are adhering to the appropriate maintenance dosage.

GLP-1 medications such as Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for weight loss and other conditions. These GLP-1 medications should be titrated monthly up to an appropriate maintenance dose. Studies demonstrating the effectiveness of these drugs at maintenance doses are well-established. However, for patients who are not achieving or maintaining a maintenance dose, alternative treatment options should be considered.

Approved maintenance doses include:

• Wegovy (semaglutide): 1.7 mg, 2.4 mg
• Zepbound (tirzepatide): 5 mg, 10 mg, 15 mg

Highmark Wholecare has conducted an analysis of drug claims for recipients receiving more than two consecutive fills of low “titration” doses of Wegovy or Zepbound below the maintenance dose. The doses defined as low “titration” doses for this review are:

• Wegovy (semaglutide): 0.25 mg, 0.5 mg, 1 mg
• Zepbound (tirzepatide): 2.5 mg

Our analysis of Highmark Wholecare pharmacy claims data indicates that one out of every eight patients are consistently filling prescriptions for a titration dose of Wegovy or Zepbound below the maintenance dose.

Ensure you regularly review patient dosages of Wegovy and Zepbound. To assist with this review, Highmark Wholecare may be sending you specific information regarding your patients who appear to be on a low dose of these medications. We understand that drug therapy must be individualized based on each patient's unique needs and overall clinical situation.